Innodata Providing Second Silicon Valley Tech Giant AI Data Annotation Across Multiple Business Segments – Yahoo Finance

NEW YORK, NY / ACCESSWIRE / September 30, 2021 /Innodata Inc. (NASDAQ:INOD), a leading data engineering company, today announced it has begun providing AI data annotation services to another Silicon Valley technology giant. This represents the second prominent Silicon Valley tech company Innodata has brought on as a customer for its AI services. Last March, Innodata announced an expanded relationship with a leading social media platform.
In terms of this latest win, Innodata will be performing AI model training and optimization across numerous business units for content moderation, intelligent document understanding, computer vision, and health records management. Innodata anticipates the win will yield approximately $1.8 million of revenue, of which it characterizes approximately $700 thousand as recurring revenue. In addition, Innodata expects to expand the relationship further over the remainder of the year and next year.
"We're finding a viable market for our solutions in Silicon Valley, especially when it comes to mission-critical AI use cases where a lot is riding on model performance," said Jack Abuhoff, Innodata Chief Executive Officer. "Unlike their incumbent providers, Innodata provides Silicon Valley tech companies with end-to-end solutions that span data sourcing, creation, and annotation, as well as global domain experts who often out-perform crowdsourced workers and intelligent platforms that reduce development time and cost."
Learn more about Innodata's AI data annotation services here and stay up to date on recent Innodata news here.
About Innodata
Innodata (NASDAQ:INOD) is a leading data engineering company. Prestigious companies across the globe turn to Innodata for help with their biggest data challenges. By combining advanced machine learning and artificial intelligence (ML/AI) technologies, a global workforce of over 3,500 subject matter experts, and a high-security infrastructure, we're helping usher in the promise of digital data and ubiquitous AI. Visit www.innodata.com to learn more.
CONTACT:
Jessie Schnurr
Innodata Inc.
jschnurr@innodata.com
201-371-8189
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Words such as "project," "believe," "expect," "can," "continue," "could," "intend," "may," "should," "will," "anticipate," "indicate," "forecast," "predict," "likely," "goals," "estimate," "plan," "potential," or the negatives thereof and other similar expressions generally identify forward-looking statements, which speak only as of the date hereof.
These forward-looking statements are based on management's current expectations, assumptions and estimates and are subject to a number of risks and uncertainties, including without limitation, the expected or potential effects of the novel coronavirus (COVID-19) pandemic and the responses of governments, the general global population, our customers, and the Company thereto; that contracts may be terminated by clients; projected or committed volumes of work may not materialize; continuing Digital Data Solutions segment reliance on project-based work and the primarily at-will nature of such contracts and the ability of these clients to reduce, delay or cancel projects; the likelihood of continued development of the markets, particularly new and emerging markets, that our services support; continuing Digital Data Solutions segment revenue concentration in a limited number of clients; potential inability to replace projects that are completed, canceled or reduced; our dependency on content providers in our Agility segment; difficulty in integrating and deriving synergies from acquisitions, joint venture and strategic investments; potential undiscovered liabilities of companies and businesses that we may acquire; potential impairment of the carrying value of goodwill and other acquired intangible assets of companies and businesses that we acquire; changes in our business or growth strategy; a continued downturn in or depressed market conditions, whether as a result of the COVID-19 pandemic or otherwise; changes in external market factors; the ability and willingness of our clients and prospective clients to execute business plans that give rise to requirements for our services; changes in our business or growth strategy; the emergence of new or growth in existing competitors; various other competitive and technological factors; our use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, client, employee or Company information, or service interruptions; and other risks and uncertainties indicated from time to time in our filings with the Securities and Exchange Commission.
Our actual results could differ materially from the results referred to in forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, uncertainty around the COVID-19 pandemic and the effects of the global response thereto and the risks discussed in Part I, Item 1A. "Risk Factors," Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, and other parts of our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2021, as updated or amended by our other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements will occur, and you should not place undue reliance on these forward-looking statements. We undertake no obligation to update or review any guidance or other forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by the Federal securities laws.
SOURCE: Innodata Inc.

View source version on accesswire.com:
https://www.accesswire.com/666100/Innodata-Providing-Second-Silicon-Valley-Tech-Giant-AI-Data-Annotation-Across-Multiple-Business-Segments

Related Quotes
In this article we are going to estimate the intrinsic value of Integer Holdings Corporation ( NYSE:ITGR ) by taking…
Sen. Richard Blumenthal asked that of Facebook’s (FB) global head of safety, Antigone Davis, during a Senate hearing on Thursday about platform’s effect on young people’s mental health. “What finsta refers to is young people setting up accounts where they want to have more privacy.” Blumenthal interrupted Davis, and asked whether finsta is indeed a product of Facebook, not Google or Apple.
Shares of electric vehicle maker Nio (NYSE: NIO) rose 3% Friday morning before losing ground as the day progressed, trading down just about 0.5% as of 1:40 p.m. today. The weakness in the EV stock's price is surprising given that Nio reached a milestone and reported solid delivery numbers for September today, even topping its own projections. Nio delivered a record number of 10,628 vehicles in total in September, up 125.7% year over year.
With the business potentially at an important milestone, we thought we'd take a closer look at NIO Inc.'s (NYSE:NIO) future prospects. NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China and is on route to expand globally.
Shares of the mid-cap biopharma Atea Pharmaceutical (NASDAQ: AVIR) are up by a respectable 21.5% as of 11:44 a.m. EDT Friday morning. The biotech's shares are taking flight today in response to a successful interim analysis for Merck's oral COVID-19 pill, molnupiravir, in a late-stage trial. Atea, for its part, is also trialing an oral COVID-19 medication, known as AT-527, with a broadly similar mechanism of action (they both interfere with viral replication).
More than 300 stocks have doubled in 2021. Let's look at some that can double again in the next three months.
Shares of healthcare company Guardant Health (NASDAQ: GH) are down 14.2% as of mid-session today on the heels of unconfirmed reports that it's interested in acquiring peer and indirect rival NeoGenomics (NASDAQ: NEO). Only citing "people familiar with the matter," Bloomberg reported on Friday that disease diagnostics Guardant Health is considering an acquisition of cancer-testing specialist NeoGenomics. Although neither NeoGenomics nor Guardant Health has confirmed they're in such discussions, the suggestion has an air of credibility.
Still earning peanuts in your savings account? These 3 income stocks might help.
Shares of Moderna were down 10.2% for the week as of the market close on Thursday. BioNTech stock closed 18.1% lower for the week, and Novavax's shares were tumbling 16.5%. Neither Moderna nor Novavax announced anything that would affect their share prices.
InMode Ltd. ( NASDAQ:INMD ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively…
Shares of ASML Holding N.V. (NASDAQ: ASML), a semiconductor equipment company, fell this week after an analyst downgraded the company's stock. Additionally, ASML's stock may have dropped earlier this week as some investors sold fast-growing tech stocks in response to rising 10-year Treasury yields. New Street analyst Pierre Ferragu downgraded ASML's shares from buy to neutral on Tuesday, with a 660 euro price target.
A lesser-known brand going after a similar market, but with a twist, is Dutch Bros (NYSE: BROS). The coffee/drink brand just went public through an initial public offering this September and is trying to grow rapidly, as Starbucks has across the United States. Is Dutch Bros the next Starbucks?
Brian Sozzi, Julie Hyman, and Brian Cheung break down the latest early market movers, which include: Zoom's stock leaping upwards after the Five9 merger agreement fell apart, Merck announcing that its experimental pill delivers effective results against COVID-19, and AMC shares surging after the company disclosed plans to repurchase debt.
Investing in stocks can be a great way to create a diversified portfolio that helps you build wealth. Unfortunately, a troubling new study conducted by Survey Monkey reveals that far too many investors are actually using social media to research their investments — and it could end up costing them. According to the Survey Monkey study, a startling percentage of new investors are relying on social media in order to research different investment ideas and determine where to put their money.
Down at the bottom, investors get into the market for the same reason: to make money. And that drive will push them to find an equity strategy that ensures solid returns, no matter what the markets do. The conventional wisdom will suggest two such strategies: buying stocks when they’re priced low, and getting into dividend stocks. The first is self-explanatory. Low priced stocks have more room for share appreciation, and Wall Street’s analysts are always on the lookout for solid buys with a low
The biggest move made by International Business Machines (NYSE: IBM) since CEO Arvind Krishna took the helm last year was the planned spinoff of the managed infrastructure services unit. Here's what IBM investors need to know. IBM shareholders will receive at least 80.1% of Kyndryl's common stock when the spinoff is complete, with IBM retaining the remaining stake.
Founded in 2010, Coupang (NYSE: CPNG) didn't take long to evolve itself into the market leader in South Korea's e-commerce industry, posting an annualized run-rate of $18 billion as of its most recent quarter. Led by Founder and CEO Bom Kim, Coupang is now taking a page out of Amazon's (NASDAQ: AMZN) playbook by focusing on long-term cash flow generation versus short-term profitability, which true investors should love to see from such a rapidly growing company.
Shares of Pfizer (NYSE: PFE) were down by 1.6% as of 11:20 a.m. EDT after having declined by as much as 3.1% earlier in the session. Pfizer's COVID vaccine partner, BioNTech (NASDAQ: BNTX), fared even worse, with its stock sliding by 11.9%. A couple of companies that have COVID-19 vaccine candidates that aren't on the market yet also felt the sting of the news from Merck and Ridgeback.

source
Connect with Chris Hood, a digital strategist that can help you with AI.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2021 AI Caosuo - Proudly powered by theme Octo